National Institute on Drug Abuse; Notice of Closed Meetings, 43502 [06-6607]

Download as PDF 43502 Federal Register / Vol. 71, No. 147 / Tuesday, August 1, 2006 / Notices here can be of great value not only to companies targeting Macular Degeneration but perhaps more broadly to those involved in complementmediated inflammatory disorders. Inventors: Michael Dean (NCI), Bert Gold (NCI) et al. Patent Status: U.S. Provisional Application No. 60/772,989 filed 13 Feb 2006 (HHS Reference No. E–042–2006/ 0–US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Susan Carson, D.Phil.; 301/435–5020; carsonsu@mail.nih.gov. Collaborative Research Opportunity: The NCI Laboratory of Genomic Diversity is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize functional or genetic tests on complement genes and proteins. Please contact Kathleen Higinbotham at 301/846–5465 for more information. Place: National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892, (301) 453–6911. hopmann@mail.nih.gov. Dated: July 24, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–12338 Filed 7–31–06; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. rwilkins on PROD1PC63 with NOTICES Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Time Sensitive Review. Date: August 16, 2006. Time: 11 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@nih.gov. Name of Committee: National Institutes of Child Health and Human Development Special Emphasis Panel, Communication of People with Mental Retardation. Date: August 15, 2006. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. VerDate Aug<31>2005 20:04 Jul 31, 2006 Jkt 208001 (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: July 25, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–6606 Filed 7–31–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: July 26, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–6607 Filed 7–31–06; 8:45 am] BILLING CODE 4140–01–M National Institute on Drug Abuse; Notice of Closed Meetings DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institutes of Health Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Pathway to Independence Award. Date: August 3, 2006. Time: 1 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 National Institute on Drug Abuse; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting to the National Advisory Council on Drug Abuse. The meeting will be open to the public as indicated below, with attendance limited to space available. individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse. Date: September 19–20, 2006. Close: September 19, 2006, 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\01AUN1.SGM 01AUN1

Agencies

[Federal Register Volume 71, Number 147 (Tuesday, August 1, 2006)]
[Notices]
[Page 43502]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6607]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Pathway to Independence Award.
    Date: August 3, 2006.
    Time: 1 p.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852, (Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401, 301-402-6626, gm145a@nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Time Sensitive Review.
    Date: August 16, 2006.
    Time: 11 a.m. to 1 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852, (Telephone Conference Call).
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
mh392g@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: July 26, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-6607 Filed 7-31-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.